Teladoc executive sells 2,500 shares under plan

Teladoc Health, Inc. executive Kelly Bliss, President, U.S. Group Health, reported an open-market sale of common stock.

Accepted by SEC EDGAR 06/30/2026 - 05:45 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Teladoc Health, Inc. executive Kelly Bliss, President, U.S. Group Health, reported an open-market sale of common stock. On June 29, 2026, she sold 2,500 shares of Teladoc Health common stock at $8.50 per share.

The filing states that this transaction was executed under a Rule 10b5-1 trading plan adopted on August 14, 2025, indicating it was pre-arranged rather than timed discretionarily. After this sale, Bliss directly holds 89,878 shares of Teladoc Health common stock.

Insider Trade Summary 10b5-1

Net Seller: 2,500 shares

Net Sell 1 txn

Insider Bliss Kelly

Role President, U.S. Group Health

Sold 2,500 shs ($21K)

Share of Position Sold 2.7%

Type	Security	Shares	Price	Value
Sale	Common Stock	2,500	$8.50	$21K

Holdings After Transaction: Common Stock — 89,878 shares (Direct)

Holdings Before and After: Common Stock, 92,378 to 89,878 shares (Direct)

Other Insiders: 5 other insiders reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (1)

1. F1. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on August 14, 2025.

Key Figures

Shares sold: 2,500 shares Sale price: $8.50 per share Shares after transaction: 89,878 shares +2 more

5 metrics

Shares sold 2,500 shares Open-market sale of common stock on June 29, 2026

Sale price $8.50 per share Price for the 2,500 Teladoc Health common shares sold

Shares after transaction 89,878 shares Direct holdings of Kelly Bliss following the sale

Net share direction -2,500 shares Net-sell direction from Form 4 transaction summary

Transactions classified as sales 1 transaction Single open-market sale reported in the filing

Key Terms

Rule 10b5-1 trading plan, open-market sale, Form 4, common stock

4 terms

Rule 10b5-1 trading plan regulatory

"The transaction was effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action is described as an open-market sale of common stock"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 regulatory

"The transaction reported in this Form 4 was effected pursuant to a plan"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

common stock financial

"Security title for the transaction is listed as Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Teladoc Health (TDOC) report for Kelly Bliss?

Teladoc Health reported that executive Kelly Bliss sold 2,500 shares of common stock. The sale was an open-market transaction at $8.50 per share and was executed under a pre-arranged Rule 10b5-1 trading plan adopted earlier.

At what price did Kelly Bliss sell Teladoc Health (TDOC) shares?

Kelly Bliss sold Teladoc Health common stock at $8.50 per share. The transaction involved 2,500 shares in a single open-market sale, as disclosed in a Form 4 insider trading report filed for Teladoc Health, Inc.

How many Teladoc Health (TDOC) shares does Kelly Bliss hold after this sale?

After the reported sale, Kelly Bliss directly holds 89,878 shares of Teladoc Health common stock. This post-transaction balance reflects the reduction of 2,500 shares sold in the disclosed open-market transaction reported on the Form 4.

Was the Teladoc Health (TDOC) insider sale by Kelly Bliss under a 10b5-1 plan?

Yes. The filing states the transaction was effected under a Rule 10b5-1 trading plan. This plan was adopted by Kelly Bliss on August 14, 2025, indicating the sale was pre-scheduled rather than a discretionary market-timed trade.

What role does Kelly Bliss hold at Teladoc Health (TDOC)?

Kelly Bliss serves as President, U.S. Group Health at Teladoc Health, Inc. Her position as an officer makes her subject to insider reporting rules, which is why her open-market stock sale was disclosed on a Form 4 filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bliss Kelly

(Last) (First) (Middle)

C/O TELADOC HEALTH, INC.,

155 E 44TH ST, SUITE 1700

(Street)

NEW YORK NEW YORK 10017

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Teladoc Health, Inc. [ TDOC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, U.S. Group Health

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/29/2026		S(1)		2,500	D	$8.5	89,878	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on August 14, 2025.

Remarks:

	/s/ Adam C. Vandervoort, Attorney-in-Fact	06/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)